Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PI3K
Pharma
Roche burnishes breast cancer portfolio with FDA nod for Itovebi
To be marketed under the brand name Itovebi, inavolisib is a threat to Novartis’ fellow PI3K inhibitor Piqray and AstraZeneca’s AKT inhibitor Truqap.
Angus Liu
Oct 10, 2024 5:30pm
Bayer, Novo separately opt to discontinue their Aliqopa, Levemir
Nov 9, 2023 9:10am
Takeda, Kyowa Kirin, Biogen—Fierce Pharma Asia
Oct 6, 2023 8:35am
'The Top Line': Alzheimer's developments, plus this week's headlines
Dec 9, 2022 6:00am
Eisai, BeiGene, Shionogi—Fierce Pharma Asia
Dec 2, 2022 10:00am
FDA adcomm votes down Secura's PI3K drug in CLL
Sep 23, 2022 3:06pm
